Volume | 134,675 |
|
|||||
News | - | ||||||
Day High | 5.445 | Low High |
|||||
Day Low | 5.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sight Sciences Inc | SGHT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.19 | 5.00 | 5.445 | 5.13 | 5.24 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,913 | 134,675 | $ 5.19 | $ 698,497 | - | 1.04 - 11.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:03:12 | priorref | 100 | $ 5.13 | USD |
Sight Sciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
253.22M | 49.55M | - | 81.06M | -55.55M | -1.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sight Sciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SGHT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.10 | 6.19 | 5.00 | 5.41 | 119,474 | -0.97 | -15.90% |
1 Month | 5.15 | 6.3425 | 4.88 | 5.49 | 197,445 | -0.02 | -0.39% |
3 Months | 4.72 | 6.3425 | 4.01 | 4.81 | 173,677 | 0.41 | 8.69% |
6 Months | 3.77 | 6.3425 | 1.04 | 3.87 | 442,594 | 1.36 | 36.07% |
1 Year | 8.79 | 11.20 | 1.04 | 4.48 | 308,514 | -3.66 | -41.64% |
3 Years | 30.00 | 42.57 | 1.04 | 11.43 | 269,563 | -24.87 | -82.90% |
5 Years | 30.00 | 42.57 | 1.04 | 11.43 | 269,563 | -24.87 | -82.90% |
Sight Sciences Description
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. |